Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amgen Inc.
New findings in the area of diabetes therapy described
July 6th, 2005
Investigators in the United States and Belgium have published new diabetes therapy data. Study 1: 11-Beta-hydroxysteroid dehydrogenase-1 is a therapeutic target for metabolic diseases. "11-Beta-hydroxysteroid dehydrogenase-1 (11-beta-HSD1) is a therapeutic target for type 2 diabetes that has stimulated the interest of many pharmaceutical companies. Mounting evidence obtained from both preclinical and clinical studies support the contention that inhibiting 11-beta-HSD1 will have a therapeutic benefit by lowering glucose output and increasing insulin sensitivity. In just over 2 years, 21 applications containing 11-beta-HSD1 inhibitors have been...
Source: Biotech Week (2005-07-06)
|
